Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 5, 2017, Pages 713-720

  Haidar, Ahmad ^a   Messier, Virginie ^b   Legault, Laurent ^c   Ladouceur, Martin ^d,e   Rabasa Lhoret, Rémi ^b,d,e,f  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Montreal Diabetes Research Center   (Canada)

Author keywords

artificial pancreas, closed loop insulin delivery, glucagon; hypoglycaemia; insulin therapy; randomised trial; type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; GLUCAGON; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; BODY MASS; CALIBRATION; CANADA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DUAL HORMONE ARTIFICIAL PANCREAS; ENERGY EXPENDITURE; FEMALE; GLUCOSE SENSOR; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; SINGLE HORMONE ARTIFICIAL PANCREAS; ADVERSE EFFECTS; AMBULATORY MONITORING; ANALYSIS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; DEVICES; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HYPERGLYCEMIA; INFUSION PUMP; INSULIN INFUSION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; QUEBEC; RISK;

ACTIVITIES OF DAILY LIVING; ADULT; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INFUSION PUMPS; INSULIN; INSULIN INFUSION SYSTEMS; MIDDLE AGED; MONITORING, AMBULATORY; PANCREAS, ARTIFICIAL; PATIENT EDUCATION AS TOPIC; QUEBEC; RISK;

EID: 85014656780     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12880     Document Type: Article

References (23)

1. Miller KM, Foster NC, Beck RW, et al.; Network TDEC. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38:971-978.
2. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45:937-948.
3. Choudhary P, Geddes J, Freeman JV, Emery CJ, Heller SR, Frier BM. Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. Diabet Med. 2010;27:666-672.
4. Pathak RD, Schroeder EB, Seaquist ER, et al.; SUPREME-DM Study Group. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005–2011. Diabetes Care. 2016;39:363-370.
5. Feltbower RG, Bodansky HJ, Patterson CC, et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. Diabetes Care. 2008;31:922-926.
6. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011;7:385-395.
7. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013;185:297-305.
8. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27.
9. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33:1282-1287.
10. Nimri R, Muller I, Atlas E, et al. MD-logic overnight control for 6 weeks of home use in patients with type 1 diabetes: Randomized crossover trial. Diabetes Care. 2014;37:3025–3032.
11. Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014;2:701-709.
12. Kropff J, Del Favero S, Place J, et al.; AP@home Consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. 2015;3(12):939–947.
13. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 2015;3:17-26.
14. Thabit H, Tauschmann M, Allen JM, et al.; for the APCam Consortium and AP@home Consortium. Home use of an artificial beta cell in Type 1 diabetes. N Engl J Med. 2015;373(22):2129–2140.
15. Leelarathna L, Dellweg S, Mader JK, et al.; AP@home Consortium. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care. 2014;37:1931-1937.
16. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
17. Blauw H, van Bon AC, Koops R, DeVries JH, on behalf of the PCDIAB consortium. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab. 2016;18(7):671–677.
18. Anderson SM, Raghinaru D, Pinsker JE, et al.; Control to Range Study Group. Multinational home use of closed-loop control is safe and effective. Diabetes Care. 2016;39:1143-1150.
19. Renard E, Farret A, Kropff J, et al.; AP@home Consortium. Day-and-night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care. 2016;39:1151-1160.
20. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
21. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2014;37:1204-1211.
22. Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes cAMP. Diabetes Care. 2014;37:2310-2316.
23. Nathan DM, Kuenen J, Borg R, et al.; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.